GlassScriptPhysician profile
Irina Robinson
NPI 1992768592
$64,782.04
in general payments reported to CMS, 2019-2025
45 companies · $7,716 in 2025
The $7,716 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $8,705 · 2021: $2,248 · 2022: $1,526 · 2023: $3,892 · 2024: $5,228 · 2025: $7,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,844 · Consulting Fee: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,550.00 |
| Food and Beverage | $3,843.94 |
| Consulting Fee | $1,442.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29,988.34 | 2019-2025 | Synthroid |
| Novo Nordisk INC | $11,733.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $11,347.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $4,816.68 | 2019-2020 | |
| Lilly USA, LLC | $1,352.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,117.90 | 2019-2025 | |
| Novo Nordisk As | $572.50 | 2024-2025 | |
| Amgen INC. | $488.43 | 2019-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $326.35 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $311.47 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Genzyme Corporation | $275.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.04 | 2020-2025 | Jardiance, Tradjenta |
| Mannkind Corporation | $215.56 | 2021-2025 | Afrezza |
| Corcept Therapeutics | $208.63 | 2020-2025 | Korlym |
| Dexcom, INC. | $184.57 | 2024-2025 | Dexcom G6 Transmitter |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.